secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001013762-24-002081
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences reports FY2024 cash of $5.8M; cloud-platform beta and FDA timeline updates
--------------------------------------------------------------------------------

- Cash and equivalents $5.8M; shareholders' equity $7.3M as of April 30, 2024.
- Net proceeds of $10.3M from stock sales; $1.1M debt converted to equity.
- Issued common stock to Mount Sinai for algorithm licenses, recognizing $1.6M intangible asset.
- MyoVista Insights cloud-platform beta completed; FDA submission targeted for mid-2025.
- MyoVista wav ECG device FDA submission expected in Q1 2025 after final testing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000101376224002081/0001013762-24-002081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000101376224002081/ea0210212-8k_heart.htm
  HTML page:      https://secwatch.observer/filing/0001013762-24-002081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer